"Rubicon Research Raises ₹1,377.5 Crore in Successful IPO with Legal Guidance from AZB & Partners and Khaitan & Co"

"Rubicon Research Limited, a Mumbai-based pharmaceutical company, has successfully raised ₹1,377.5 crore through an initial public offering (IPO). The IPO included a fresh issue and an offer for sale by General Atlantic Singapore RR Pte. Ltd. AZB & Partners advised Rubicon on the IPO, while Khaitan & Co provided guidance to the Book Running Lead Managers, which included Axis Capital Limited and others. Rubicon specializes in developing and marketing branded specialty products for pharmaceutical companies."

In a recent transaction, AZB & Partners and Khaitan & Co played significant roles in advising on the initial public offering (IPO) of Rubicon Research Limited. AZB & Partners advised Rubicon Research, while Khaitan & Co provided counsel to the Book Running Lead Managers, which included Axis Capital Limited, IIFL Capital Services Limited, JM Financial Limited, and SBI Capital Markets Limited. Rubicon Research Limited successfully raised ₹1,377.5 crore through its IPO, which consisted of a fresh issue and an offer for sale by General Atlantic Singapore RR Pte. Ltd., the promoter selling shareholder. The company, based in Mumbai, specializes in developing, manufacturing, and marketing branded specialty products for pharmaceutical companies. The transaction team from AZB & Partners included Subhayu Sen (Partner), Ayush Mohata (Partner), and Aparna Bagree (Partner), along with Senior Associate Johann Valladares and Associates Aayush Virani, Avantika Tanwar, and Mehar Sharma.

"Rubicon Research Raises ₹1,377.5 Crore in Successful IPO with Legal Guidance from AZB & Partners and Khaitan & Co"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads